Pipeline
A focused portfolio with a clear path to the clinic
Our pipeline reflects a focused portfolio of bispecific antibody programmes, each addressing a defined biological hypothesis with a clear path to clinical development.
Coloured bars indicate the current stage of development for each programme. Indications and targets for undisclosed programmes are withheld for competitive reasons.
BVB-101
BVB-101 is a bispecific antibody engineered to simultaneously engage a tumour-associated antigen and a co-stimulatory immune receptor, enabling conditional immune activation within the tumour microenvironment.
Preclinical data demonstrate strong selectivity, dose-dependent tumour regression in relevant in vivo models, and a developability profile suitable for GMP manufacturing. The programme is currently advancing through IND-enabling studies in partnership with selected CROs and CDMOs.
Discuss a partnershipPartner on a programme
We are actively engaging CDMO and development partners as we advance toward IND filing.